Higher Risk of Venous Thrombosis During Early Use of Oral Contraceptives in Women With Inherited Clotting Defects
Open Access
- 10 January 2000
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 160 (1) , 49-52
- https://doi.org/10.1001/archinte.160.1.49
Abstract
RESULTS OF recent studies1-4 show that the risk for venous thrombosis is highest during the initial period of oral contraceptive use. This confirms a clinical impression that has not been studied extensively.5-7 It was previously reported3,8 that factor V Leiden mutation, which leads to resistance to activated protein C and was found in about 1 of 5 patients with venous thrombosis, displays a strong interaction with use of oral contraceptives. Other inherited clotting defects that are themselves risk factors for venous thrombosis, such as protein C deficiency, protein S deficiency, antithrombin deficiency, and prothrombin 20210 A mutation, might also lead to a high risk of venous thrombosis when combined with oral contraceptive use.9This publication has 13 references indexed in Scilit:
- Risk of Venous Thrombosis With Use of Current Low-Dose Oral Contraceptives Is Not Explained by Diagnostic Suspicion and Referral BiasArchives of internal medicine (1960), 1999
- Newer Oral Contraceptives and the Risk of Venous ThromboembolismContraception, 1998
- First-time use of newer oral contraceptives and the risk of venous thromboembolismContraception, 1997
- Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control studyBMJ, 1996
- Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutationThe Lancet, 1994
- Resistance to activated protein C is reduced in women using oral contraceptivesBlood Coagulation & Fibrinolysis, 1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia StudyThe Lancet, 1993
- Investigation of Relation between Use of Oral Contraceptives and Thromboembolic Disease. A Further ReportBMJ, 1969
- Investigation of relation between use of oral contraceptives and thromboembolic disease.BMJ, 1968